CN101166528B - 3-氨基咔唑的苯甲酰衍生物在制备治疗与前列腺素e2(pge2)的产生有关的疾病的药物中的应用 - Google Patents

3-氨基咔唑的苯甲酰衍生物在制备治疗与前列腺素e2(pge2)的产生有关的疾病的药物中的应用 Download PDF

Info

Publication number
CN101166528B
CN101166528B CN2006800144162A CN200680014416A CN101166528B CN 101166528 B CN101166528 B CN 101166528B CN 2006800144162 A CN2006800144162 A CN 2006800144162A CN 200680014416 A CN200680014416 A CN 200680014416A CN 101166528 B CN101166528 B CN 101166528B
Authority
CN
China
Prior art keywords
aminocarbazole
chemical compound
prostaglandin
group
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800144162A
Other languages
English (en)
Chinese (zh)
Other versions
CN101166528A (zh
Inventor
L·普伦扎尼
G·曼加诺
I·科勒塔
M·A·埃里斯
N·卡佐拉
G·弗尔洛蒂
C·毛杰里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angelini Acraf SpA
Original Assignee
Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aziende Chimiche Riunite Angelini Francesco ACRAF SpA filed Critical Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Publication of CN101166528A publication Critical patent/CN101166528A/zh
Application granted granted Critical
Publication of CN101166528B publication Critical patent/CN101166528B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
CN2006800144162A 2005-05-19 2006-05-03 3-氨基咔唑的苯甲酰衍生物在制备治疗与前列腺素e2(pge2)的产生有关的疾病的药物中的应用 Expired - Fee Related CN101166528B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2005A000909 2005-05-19
IT000909A ITMI20050909A1 (it) 2005-05-19 2005-05-19 Uso di un benzoil derivato dal 3-ammino-carbazolo per la produzione di un farmaco per il trattamento di un disturbo associato alla produzione di prostaglandina e2-pge2-
PCT/EP2006/004348 WO2006122680A1 (en) 2005-05-19 2006-05-03 Use of a benzoyl derivative of 3-aminocarbazole for the treatment of a disorder associated with the production of prostaglandin e2 (pge2)

Publications (2)

Publication Number Publication Date
CN101166528A CN101166528A (zh) 2008-04-23
CN101166528B true CN101166528B (zh) 2011-06-15

Family

ID=35219704

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800144162A Expired - Fee Related CN101166528B (zh) 2005-05-19 2006-05-03 3-氨基咔唑的苯甲酰衍生物在制备治疗与前列腺素e2(pge2)的产生有关的疾病的药物中的应用

Country Status (23)

Country Link
US (1) US8686021B2 (enExample)
EP (1) EP1881826B1 (enExample)
JP (1) JP5086991B2 (enExample)
KR (1) KR101312579B1 (enExample)
CN (1) CN101166528B (enExample)
AR (1) AR054126A1 (enExample)
AT (1) ATE473739T1 (enExample)
AU (1) AU2006246688B2 (enExample)
BR (1) BRPI0609718A2 (enExample)
CA (1) CA2604562C (enExample)
DE (1) DE602006015457D1 (enExample)
DK (1) DK1881826T3 (enExample)
EA (1) EA012724B1 (enExample)
ES (1) ES2347174T3 (enExample)
GE (1) GEP20094738B (enExample)
IL (1) IL186072A (enExample)
IT (1) ITMI20050909A1 (enExample)
MX (1) MX2007013491A (enExample)
PL (1) PL1881826T3 (enExample)
PT (1) PT1881826E (enExample)
SI (1) SI1881826T1 (enExample)
UA (1) UA94044C2 (enExample)
WO (1) WO2006122680A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20051523A1 (it) 2005-08-03 2007-02-04 Acraf Composto del 3-ammino-carbazolo composizione farmaceutica che lo contiene e metodo per prepararlo
EP2119705A1 (en) 2008-05-14 2009-11-18 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. 3-Aminocarbozole compound, pharmaceutical composition containing it and preparation method therefor
US8880004B2 (en) 2009-05-14 2014-11-04 Qualcomm Incorporated System and method for resolving conflicts between air interfaces in a wireless communication system

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399631B1 (en) * 1999-07-23 2002-06-04 Pfizer Inc. Carbazole neuropeptide Y5 antagonists
WO2002096902A1 (en) * 2001-05-29 2002-12-05 Boehringer Ingelheim International Gmbh Carbazole derivatives and their use for the preparation of pharmaceutical compositions for the treatment of npy related diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002241368A (ja) * 1997-02-18 2002-08-28 Shionogi & Co Ltd 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物
AU6000900A (en) 1999-07-23 2001-02-13 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
JP2003507424A (ja) * 1999-08-26 2003-02-25 ブリストル−マイヤーズ スクイブ カンパニー Ｎｐｙアンタゴニスト：スピロイソキノリノン誘導体
CA2403307A1 (en) * 2001-10-23 2003-04-23 Neurogen Corporation Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives
KR20030042344A (ko) * 2001-11-22 2003-05-28 한국생명공학연구원 에레모필란계 화합물 또는 곰취추출물을 유효성분으로함유하는 염증질환 치료제, 면역질환 치료제, 및 암 치료제
ES2193875B2 (es) * 2002-04-09 2005-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
KR100402714B1 (ko) * 2002-12-23 2003-11-13 한국생명공학연구원 디테르펜계 화합물을 염증질환, 면역질환 및 암 치료제로사용하는 신규한 용도

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399631B1 (en) * 1999-07-23 2002-06-04 Pfizer Inc. Carbazole neuropeptide Y5 antagonists
WO2002096902A1 (en) * 2001-05-29 2002-12-05 Boehringer Ingelheim International Gmbh Carbazole derivatives and their use for the preparation of pharmaceutical compositions for the treatment of npy related diseases

Also Published As

Publication number Publication date
CN101166528A (zh) 2008-04-23
EP1881826A1 (en) 2008-01-30
IL186072A0 (en) 2008-08-07
CA2604562C (en) 2013-09-17
ITMI20050909A1 (it) 2006-11-20
IL186072A (en) 2012-05-31
ES2347174T3 (es) 2010-10-26
PT1881826E (pt) 2010-08-05
AU2006246688A1 (en) 2006-11-23
UA94044C2 (ru) 2011-04-11
JP2008540591A (ja) 2008-11-20
JP5086991B2 (ja) 2012-11-28
KR101312579B1 (ko) 2013-09-30
KR20080018898A (ko) 2008-02-28
SI1881826T1 (sl) 2010-10-29
WO2006122680A1 (en) 2006-11-23
GEP20094738B (en) 2009-07-27
MX2007013491A (es) 2008-01-24
PL1881826T3 (pl) 2010-12-31
CA2604562A1 (en) 2006-11-23
AR054126A1 (es) 2007-06-06
US20080287518A1 (en) 2008-11-20
BRPI0609718A2 (pt) 2011-10-18
EP1881826B1 (en) 2010-07-14
EA012724B1 (ru) 2009-12-30
DE602006015457D1 (de) 2010-08-26
HK1119571A1 (en) 2009-03-13
ATE473739T1 (de) 2010-07-15
EA200702534A1 (ru) 2008-04-28
AU2006246688B2 (en) 2011-09-22
US8686021B2 (en) 2014-04-01
DK1881826T3 (da) 2010-11-01

Similar Documents

Publication Publication Date Title
Richard et al. Pharmaceutical treatment of osteoarthritis
Cho et al. Study of osteoarthritis treatment with anti‐inflammatory drugs: cyclooxygenase‐2 inhibitor and steroids
Schoenberger et al. Nonsteroidal Anti‐Inflammatory Drugs for Retinal Disease
Guedes et al. Soluble epoxide hydrolase activity and pharmacologic inhibition in horses with chronic severe laminitis
Kivett et al. Evaluation of the safety of a combination of oral administration of phenylbutazone and firocoxib in horses
Quintanilla et al. Administration of N-acetylcysteine Plus acetylsalicylic acid markedly inhibits nicotine reinstatement following chronic oral nicotine intake in female rats
NO175148B (no) Fremgangsmåte for fremstilling av et indomethacinsalt av et toverdig metall valgt fra kobber, sink, kobolt og nikkel
CN116115619B (zh) 利培酮在治疗器官纤维化中的应用
CA2395711A1 (en) Pharmaceutical compositions
CN101166528B (zh) 3-氨基咔唑的苯甲酰衍生物在制备治疗与前列腺素e2(pge2)的产生有关的疾病的药物中的应用
CN1299278A (zh) 血管生成抑制
JP2009539877A5 (enExample)
JP2025513474A (ja) 好中球性皮膚疾患の治療
CN116942668A (zh) Glyt1抑制剂在治疗器官纤维化中的应用
JP5979658B2 (ja) 破骨細胞が関与する疾患の予防剤及び／又は治療剤
Pongkorpsakol et al. Fatty acid and mineral receptors as drug targets for gastrointestinal disorders
Cole Pharmacology of nonsteroidal anti‐inflammatory drugs
US8841317B2 (en) Noscapine and analogs and methods related thereto
KR102619489B1 (ko) 폴마콕시브 및 트라마돌을 포함하는 급, 만성 통증 치료용 약제학적 조성물
JP2015003902A (ja) 血管新生阻害剤
Wen et al. Functions of Macrophages, T Cells, and Neutrophils in the Synovial Microenvironment of Osteoarthritis
MODEL PHARMACEUTICAL SCIENCES
Porwal et al. Efficacy and Tolerability of Fixed‐Dose Combination of Dexketoprofen and Dicyclomine Injection in Acute Renal Colic
JP2008530224A (ja) 粘膜組織の異常の治療のための方法及び組成物
Weng¹t et al. The common link between sleep apnea syndrome and

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1119571

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1119571

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110615

Termination date: 20180503

CF01 Termination of patent right due to non-payment of annual fee